Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Programmable Medicine Operating Company holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action. This action is assigned to 1 distinct examiner and 1 distinct art unit. VU, JAKE MINH is the busiest examiner, with 1 pending office action. The prosecution of this portfolio is currently very focused, with only 1 pending office action being reviewed by 1 distinct examiner.
The involvement of 1 distinct art unit indicates that the Biotechnology & Pharmaceuticals technology is being evaluated within a specific group. Practitioners should focus on the specific requirements of VU, JAKE MINH to resolve the 1 pending office action. The examiner's individual interpretation of the 1 pending office action will be the primary factor in the company's patenting progress. Practitioners should focus on the specific requirements of the 1 distinct art unit to move the case forward. This focused approach allows for a dedicated response to the examiner's specific concerns regarding the 1 pending office action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VU, JAKE MINH | 1 | 41.1% | +27.2% |
| PIHONAK, SARAH | 1 | 61.3% | +42.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18016262 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO INJURED KIDNEY | PIHONAK, SARAH | 22d |
| 18034551 | RADIOLABELED ETHER DENDRIMER CONJUGATES FOR PET IMAGING AND RADIOTHERAPY | VU, JAKE MINH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18016262 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO INJURED KIDNEY | PIHONAK, SARAH | 22d |
| 18034551 | RADIOLABELED ETHER DENDRIMER CONJUGATES FOR PET IMAGING AND RADIOTHERAPY | VU, JAKE MINH | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18034551 | RADIOLABELED ETHER DENDRIMER CONJUGATES FOR PET IMAGING AND RADIOTHERAPY | VU, JAKE MINH | 1618 | §102§103§112 | Non-Final OA | — | Pending | Apr 28, 2023 |
| 18016262 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO INJURED KIDNEY | PIHONAK, SARAH | 1627 | §103§112 | Final Rejection | 22d | Pending | Jan 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial